Belviq Oral Tablet 10Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Belviq: Oral tablet (10mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_17313.JPG
Belviq 10mg Tablet
Eisai Inc
Pill Identification: A  |  10

What is this Medicine?

LORCASERIN (lor ca SER in) is used to promote and maintain weight loss in obese patients. This medicine should be used with a reduced calorie diet and, if appropriate, an exercise program.

CVS Pharmacy Patient Statistics for Belviq: Oral tablet(10mg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Belviq 10mg Tablet

NDC: 628560529
  • Prescription Required
  • Federally Controlled Drug
    (CSA Schedule)
  • FDA Approved





Storage Information
Store at room temperature (between 59 to 86 degrees F)
Protect from extreme heat
Protect from moisture
Belviq 10mg Tablet
Drug Image file DrugItem_17313.JPG
Eisai Inc
Pill Identification: A  |  10
Shape: round
Color: blue

Reported Side Effects for Belviq 10mg Tablet

Skin Rash Incidence:
<2.1%*
Severity: MILD
Onset: EARLY
Muscle And/Or Bone Pain Incidence:
<2.0%*
Severity: MILD
Onset: EARLY
Low Lymphocytes Incidence:
<0.4%*
Severity: MODERATE
Onset: DELAYED
Stiff Heart Vavle Incidence:
<2.4%*
Severity: SEVERE
Onset: DELAYED
Blurred Vision Incidence:
<6.3%*
Severity: MODERATE
Onset: EARLY
Back Pain Incidence:
<11.7%*
Severity: MILD
Onset: DELAYED
Fluid Retention Incidence:
<4.7%*
Severity: MODERATE
Onset: DELAYED
Muscle Cramps Incidence:
<4.7%*
Severity: MILD
Onset: DELAYED
Low White Blood Cell Counts Incidence:
<0.4%*
Severity: MODERATE
Onset: DELAYED
Infection Incidence:
<13.7%*
Severity: MILD
Onset: DELAYED
Dry Eyes Incidence:
<6.3%*
Severity: MILD
Onset: EARLY
Low White Blood Cells Incidence:
<0.4%*
Severity: MODERATE
Onset: DELAYED
Cough Incidence:
<8.2%*
Severity: MILD
Onset: DELAYED
Low Blood Sugar Incidence:
<29.3%*
Severity: MODERATE
Onset: EARLY
High Blood Pressure Incidence:
<5.1%*
Severity: MODERATE
Onset: EARLY
High Prolactin Level Incidence:
0.1-6.7%*
Severity: MODERATE
Onset: DELAYED
Excessive Sweating Incidence:
0.1%*
Severity: MILD
Onset: DELAYED
Elated Mood Incidence:
0.2%*
Severity: MODERATE
Onset: EARLY
Confusion Incidence:
0.2%*
Severity: MODERATE
Onset: EARLY
Slow Heart Beat Incidence:
0.3%*
Severity: SEVERE
Onset: RAPID
Shaking Incidence:
0.3%*
Severity: MILD
Onset: EARLY
Thoughts Of Suicide Incidence:
0.6%*
Severity: SEVERE
Onset: DELAYED
Chills Incidence:
1.0%*
Severity: MILD
Onset: RAPID
Decreased Thinking Incidence:
2.3%*
Severity: MODERATE
Onset: EARLY
Depression Incidence:
2.3%*
Severity: MODERATE
Onset: DELAYED
Tooth Pain Incidence:
2.7%*
Severity: MILD
Onset: DELAYED
Inability To Sleep Incidence:
3.5%*
Severity: MILD
Onset: EARLY
Nervousness Incidence:
3.5%*
Severity: MILD
Onset: DELAYED
Vomiting Incidence:
3.8%*
Severity: MILD
Onset: EARLY
Dry Mouth Incidence:
5.3%*
Severity: MILD
Onset: EARLY
Constipation Incidence:
5.8%*
Severity: MODERATE
Onset: DELAYED
Loose Stools Incidence:
6.5%*
Severity: MILD
Onset: EARLY
Lightheadedness Incidence:
7.0-8.5%*
Severity: MILD
Onset: EARLY
Tired Incidence:
7.2-7.4%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
8.3-9.4%*
Severity: MILD
Onset: EARLY
Headache Incidence:
14.5-16.8%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

SECOND Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

THIRD Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Belviq

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.